Research

CTNC has a tradition of excellence in clinical research, having participated in over 50 clinical trials. All of us at CTNC want our patients to be aware of our dedication to clinical research. Our physicians have extensive experience and are committed to advancing medical science through clinical research studies.

What is Clinical Research?

The National Institutes of Health defines “clinical research” as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual.Clinical research includes:

Patient-oriented research – This type of research involves a particular person or group of people, or uses materials from humans. This research can include 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies

Epidemiological and behavioral studies – These types of studies examine the distribution of disease, the factors that affect health, and how people make health-related decisions.

Outcomes and health services research – These studies seek to identify the most effective and most efficient interventions, treatments, and services.

ACTIVE TRIALS: ENROLLING

Alzheimer's Disease:

ANVS-22002

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

Essential Tremors:

324-ETD-202

Phase 2 Double-blind, Randomized, Placebo Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

Progressive
Supranuclear Palsy:

a35-009

A Phase 3 study of safety and efficacy in AMX0035 in Progressive Supranuclear Palsy.

Status: Open Enrollment

Parkinson's Disease:

BK-JM-201

A Randomized, Double-Blind, Placebo-Controlled, Two Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

CRL_18_06

A Phase 2 Study in Early Parkinson's Disease Patients Evaluating The Safety tnd Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

CVL-751-002

A Phase 3, Double-Blind, Randomized placebo-controlled, parallel-group, flexible-dose, 27-week trail to evaluate the efficacy, safety, and tolerability of Tavapadon in early Parkinson’s Disease

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

IkT-148009-201

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

JZP385-202

A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s Disease

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

PD0060

A Multicenter Phase 2, Double-Blind, Placebo-controlled, Randomized, Parallel group study to evaluate the efficacy, safety, tolerability and Pharmacokinetics or UCB0022 in study participants with advanced Parkinson’s Disease.

Status: Open Enrollment

Principal Investigator:
Dr. Peckham

283PD201

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo Controlled Study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease.

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

ACTIVE TRIALS: ONGOING

Alzheimer's Disease:

ANVS-22001

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson’s disease

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

BN42358

A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson’s Disease

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

BP39529

A Randomized, Double-Blind, Placebo- Controlled 52 week phase II Study to evaluate the efficacy of IV RO7046015 (PRX002) in participants with early Parkinson’s disease safety and tolerability of ABBV-951 in subjects with Parkinson's Disease

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

CVL-751-PD-003

A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel-Group, Flexible-Dose, 27-Week trial to evaluate the efficacy, safety, and tolerability of Tavapadon as adjunctive therapy for Parkinson’s Disease in Levodopa-treated adults with motor fluctuations (TEMPO-3 TRIAL)

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

CVL-751-PD-004

58-Week open-label Trial of Tavapadon in Parkinson’s Disease

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

UPCOMING TRIALS:

CN008-0003

A Phase 2, Randomized, double-lind, placebo-controlled, Multicenter study
assessing the efficacy, safety and tolerability of BMS-986446, and Anti-MTBR Tau Monoclonal Antibody, in participants with Early Alzheimer’s Disease.

FNP223-CT-2301

A randomized, double-blind placebo-controlled, study to asses the safety,
efficacy, and pharmacokinetics of FNP-223 (oral formulation) for the treatment of Progressive Supranuclear Palsy.

TV56286-NDG-20039

A Multi-centered, double-blind, Randomized, Placebo-controlled, Parallel group Phase 2 study pf TEV-562 for the treatment of patients with Multiple system atrophy.

RESEARCH TEAM